Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 11, 2023
Discovery & Translation

Bacteria to detect tumors; plus Netris’ mAb to block EMT in cancer and more

BioCentury’s roundup of translational innovations
BioCentury | Aug 19, 2017
Product Development

Restoring dependence

How Netris’ dependence receptor programs kill cancer stem cells missed by other drugs
BioCentury | Mar 29, 2017
Clinical News

NP137: Ph I started

BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

BioCentury | May 7, 2015
Translation in Brief

NYU cuts to the bone with MRCT

Why NYU thinks MRCT partnership can develop antibodies for osteolysis
BioCentury | Jun 19, 2014
Distillery Techniques

Technology: Markers

BioCentury | Mar 27, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

BioCentury | Apr 16, 2009
Distillery Therapeutics

This week in therapeutics

Items per page:
1 - 10 of 13